National Cancer Institute, Cancer Treatment Section, Executive Plaza South, Rm. 603, 6120 Executive Blvd. Bethesda, Md. 20892-7220

A -- SYNTHESIS OF CONGENERS AND PRODRUGS SOL NCI-CM-67246-74 DUE 110695 POC Odessa S. Henderson, Contract Specialist, 301-496-8620, Carolyn L. Swift, Contracting Officer, 301-496-8620. The Drug Synthesis and Chemistry Branch (DS&CB), Developmental Therapeutics Program (DTP), Division of Cancer Treatment (DCT) of the National Cancer Institute (NCI) is seeking contractors with expertise in chemical synthesis and drug design to synthesize a variety of compounds for evaluation as potential anti-cancer and anti-HIV agents. The assigned objectives of this project are to design and synthesize the following: (a) congeners of lead compounds having confirmed activity to enhance activity or potency; (b) prodrugs with structural modifications that may provide altered pharmacokinetics, altered drug transport, improved bio-availability through increased water solubility or increased chemical stability; (c) other altered structures that possess elements of both congener and prodrug; and (d) compounds related to natural products, e.g., alkaloids, heterocycles, nucleosides, peptides and the like. Each contractor should have available a fully operational facility, including all necessary equipment and instrumentation for all aspects of the contract. The nature of this project requires that the following restriction be applied: ''The NCI signs legally binding agreements with certain suppliers (often pharmaceutical or chemical companies) which state that all information on compounds submitted by the supplier will be held confidential.'' The successful offeror will be expected to synthetically modify such commercially confidential (discreet) materials. Thus, pharmaceutical or chemical companies could obtain valuable data on new lead compounds. Therefore, in order to honor the confidentiality agreement with the original supplier, the NCI believes that the compounds cannot be sent to potential competitors of the supplier, and thus pharmaceutical and chemical companies must be excluded from the competition. The intent of the exclusion is to prevent companies who market chemicals or drugs on the open marken from gaining undue competitive advantage by access to privileged inside information. The exclusion does not apply to companies and/or laboratories whose synthesis activities are performed on a specific order from another party. It is understood that such companies do not sell drugs or chemicals on the open market and are thus not in a position to profit from access to privileged information from NCI. It is anticipated that 6,032 hours per award per year will be required for this project. This is a recompetition of contracts currently held by the Purdue Research Foundation (N01-CM-17512), Research Foundation of the State University of New York at Buffalo (N01-CM-17569), Georgia Tech Research Foundation (N01-CM-17570) and (N01-CM-47012) and University of Tennessee (N01-CM-47038). It is anticipated that four (4) cost-reimbursement contracts will be awarded for a period of three (3) years, with two one year options, beginning on or about August 1, 1996. no collect calls will be accepted. (0223)

Loren Data Corp. http://www.ld.com (SYN# 0001 19950814\A-0001.SOL)